130 related articles for article (PubMed ID: 22059882)
1. 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.
Stock NS; Bain G; Zunic J; Li Y; Ziff J; Roppe J; Santini A; Darlington J; Prodanovich P; King CD; Baccei C; Lee C; Rong H; Chapman C; Broadhead A; Lorrain D; Correa L; Hutchinson JH; Evans JF; Prasit P
J Med Chem; 2011 Dec; 54(23):8013-29. PubMed ID: 22059882
[TBL] [Abstract][Full Text] [Related]
2. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.
Stock N; Baccei C; Bain G; Broadhead A; Chapman C; Darlington J; King C; Lee C; Li Y; Lorrain DS; Prodanovich P; Rong H; Santini A; Zunic J; Evans JF; Hutchinson JH; Prasit P
Bioorg Med Chem Lett; 2010 Jan; 20(1):213-7. PubMed ID: 19914828
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.
Lorrain DS; Bain G; Correa LD; Chapman C; Broadhead AR; Santini AM; Prodanovich P; Darlington JV; Hutchinson JH; King C; Lee C; Baccei C; Li Y; Arruda JM; Evans JF
J Pharmacol Exp Ther; 2009 Dec; 331(3):1042-50. PubMed ID: 19749079
[TBL] [Abstract][Full Text] [Related]
4. 5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).
Hutchinson JH; Li Y; Arruda JM; Baccei C; Bain G; Chapman C; Correa L; Darlington J; King CD; Lee C; Lorrain D; Prodanovich P; Rong H; Santini A; Stock N; Prasit P; Evans JF
J Med Chem; 2009 Oct; 52(19):5803-15. PubMed ID: 19739647
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation.
Lorrain DS; Bain G; Correa LD; Chapman C; Broadhead AR; Santini AM; Prodanovich PP; Darlington JV; Stock NS; Zunic J; King CD; Lee C; Baccei CS; Stearns B; Roppe J; Hutchinson JH; Prasit P; Evans JF
Eur J Pharmacol; 2010 Aug; 640(1-3):211-8. PubMed ID: 20519143
[TBL] [Abstract][Full Text] [Related]
6. 5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration.
Stock N; Baccei C; Bain G; Chapman C; Correa L; Darlington J; King C; Lee C; Lorrain DS; Prodanovich P; Santini A; Schaab K; Evans JF; Hutchinson JH; Prasit P
Bioorg Med Chem Lett; 2010 Aug; 20(15):4598-601. PubMed ID: 20566292
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP).
Bain G; King CD; Rewolinski M; Schaab K; Santini AM; Shapiro D; Moran M; van de Wetering de Rooij S; Roffel AF; Schuilenga-Hut P; Milne GL; Lorrain DS; Li Y; Arruda JM; Hutchinson JH; Prasit P; Evans JF
Clin Pharmacol Ther; 2010 Apr; 87(4):437-44. PubMed ID: 20182424
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.
Bain G; King CD; Schaab K; Rewolinski M; Norris V; Ambery C; Bentley J; Yamada M; Santini AM; van de Wetering de Rooij J; Stock N; Zunic J; Hutchinson JH; Evans JF
Br J Clin Pharmacol; 2013 Mar; 75(3):779-90. PubMed ID: 22803688
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
10. Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.
Hutchinson JH; Charleson S; Evans JF; Falgueyret JP; Hoogsteen K; Jones TR; Kargman S; Macdonald D; McFarlane CS; Nicholson DW
J Med Chem; 1995 Oct; 38(22):4538-47. PubMed ID: 7473582
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship.
Hayashi S; Sumi Y; Ueno N; Murase A; Takada J
Biochem Pharmacol; 2011 Oct; 82(7):755-68. PubMed ID: 21741371
[TBL] [Abstract][Full Text] [Related]
12. Thiopyrano[2,3,4-cd]indoles as 5-lipoxygenase inhibitors: synthesis, biological profile, and resolution of 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5 -dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid.
Hutchinson JH; Riendeau D; Brideau C; Chan C; Falgueyret JP; Guay J; Jones TR; Lépine C; Macdonald D; McFarlane CS
J Med Chem; 1994 Apr; 37(8):1153-64. PubMed ID: 8164257
[TBL] [Abstract][Full Text] [Related]
13. Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
Wu C; Decker ER; Blok N; Bui H; You TJ; Wang J; Bourgoyne AR; Knowles V; Berens KL; Holland GW; Brock TA; Dixon RA
J Med Chem; 2004 Apr; 47(8):1969-86. PubMed ID: 15055997
[TBL] [Abstract][Full Text] [Related]
14. Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases.
Lemurell M; Ulander J; Winiwarter S; Dahlén A; Davidsson Ö; Emtenäs H; Broddefalk J; Swanson M; Hovdal D; Plowright AT; Pettersen A; Rydén-Landergren M; Barlind J; Llinas A; Herslöf M; Drmota T; Sigfridsson K; Moses S; Whatling C
J Med Chem; 2015 Jan; 58(2):897-911. PubMed ID: 25478788
[TBL] [Abstract][Full Text] [Related]
15. Effects of a FLAP inhibitor, GSK2190915, in asthmatics with high sputum neutrophils.
Chaudhuri R; Norris V; Kelly K; Zhu CQ; Ambery C; Lafferty J; Cameron E; Thomson NC
Pulm Pharmacol Ther; 2014 Feb; 27(1):62-9. PubMed ID: 24333186
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of endo- and exo-aryl-substitutions and central scaffold modifications on diphenyl substituted alkanes as 5-lipoxygenase activating protein inhibitors.
Chu L; Armstrong HM; Chang LL; Cheng AF; Colwell L; Cui J; Evans J; Galka A; Goulet MT; Hayes N; Lo J; Menke J; Ok HO; Ondeyka DL; Patel M; Quaker GM; Sings H; Witkin SL; Zhao A; Ujjainwalla F
Bioorg Med Chem Lett; 2012 Jun; 22(12):4133-8. PubMed ID: 22578458
[TBL] [Abstract][Full Text] [Related]
17. Symmetrical bis(heteroarylmethoxyphenyl)alkylcarboxylic acids as inhibitors of leukotriene biosynthesis.
Kolasa T; Gunn DE; Bhatia P; Basha A; Craig RA; Stewart AO; Bouska JB; Harris RR; Hulkower KI; Malo PE; Bell RL; Carter GW; Brooks CD
J Med Chem; 2000 Aug; 43(17):3322-34. PubMed ID: 10966751
[TBL] [Abstract][Full Text] [Related]
18. Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816.
Hutchinson JH; Riendeau D; Brideau C; Chan C; Delorme D; Denis D; Falgueyret JP; Fortin R; Guay J; Hamel P
J Med Chem; 1993 Sep; 36(19):2771-87. PubMed ID: 8410991
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
20. A Single Amino Acid Difference between Mouse and Human 5-Lipoxygenase Activating Protein (FLAP) Explains the Speciation and Differential Pharmacology of Novel FLAP Inhibitors.
Blevitt JM; Hack MD; Herman K; Chang L; Keith JM; Mirzadegan T; Rao NL; Lebsack AD; Milla ME
J Biol Chem; 2016 Jun; 291(24):12724-12731. PubMed ID: 27129215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
